Cincinnati Children's Hospital Medical Center, OH, USA.
Biomark Med. 2012 Jun;6(3):273-82. doi: 10.2217/bmm.12.27.
Acute kidney injury is a common and significant complication among pediatric patients with congenital heart disease, occurring most commonly after cardiopulmonary bypass. Current laboratory methods of diagnosis are not timely enough to guide management decisions, thus spurring interest in discovering new biomarkers of acute injury. Several promising candidates, including NGAL, IL-18 and KIM-1, have been the subject of recent investigation and may facilitate earlier and more accurate diagnosis of renal injury within this cohort. There is little evidence demonstrating that it will be possible to rely upon one particular biomarker as a single agent, and evidence supports that the use of biomarker panels will be most effective. Further clinical validation and broader commercial availability of these novel biomarkers will probably revolutionize the care of pediatric cardiac patients with renal injury.
急性肾损伤是先天性心脏病儿科患者的常见且严重的并发症,最常发生在心肺旁路手术后。目前的诊断实验室方法不够及时,无法指导管理决策,因此人们对发现急性损伤的新生物标志物产生了兴趣。几种有前途的候选标志物,包括 NGAL、IL-18 和 KIM-1,已经成为最近研究的主题,并且可能有助于更早、更准确地诊断该队列中的肾损伤。几乎没有证据表明有可能依赖于一种特定的生物标志物作为单一药物,并且有证据表明使用生物标志物谱将是最有效的。这些新型生物标志物的进一步临床验证和更广泛的商业应用可能会彻底改变对患有肾损伤的儿科心脏患者的治疗。